World of DTC Marketing

JUNE 5, 2021

There is disagreement whether obesity is really considered a disease or a behavioral risk factor, similar to smoking, alcohol, and substance abuse that may lead to disease. Some of the environmental conditions that lead to obesity are physical activity, alcohol consumption, socioeconomic status, parent feeding behavior, and diet.

Government 193

Government Medicine Food Management 193

European Pharmaceutical Review

NOVEMBER 2, 2022

The Cedars-Sinai Board of Governors Regenerative Medicine Institute and the Smidt Heart Institute will lead the project. The advanced facility will be based on the Regenerative Medicine Clinic established at Cedars-Sinai in 2014, developing clinical trials for neurological, cardiovascular, musculoskeletal and autoimmune diseases.

Food and Drug Administration 98

Food and Drug Administration Medicine Training Electronics 98

European Pharmaceutical Review

APRIL 29, 2024

Pfizer licensed BEQVEZ from Spark Therapeutics in December 2014. BEQVEZ is currently being reviewed by the European Medicines Agency (EMA), Pfizer confirmed. Article: The evolution of AAVs in cell and gene therapy The post Novel haemophilia B gene therapy approved appeared first on European Pharmaceutical Review.

Food and Drug Administration 96

Food and Drug Administration Medicine FDA Food 96

pharmaphorum

OCTOBER 3, 2022

One of a group of muscular dystrophies, DMD leads to a gradual loss of muscle function, often with children having to use a wheelchair by their early adolescence. Translarna has had European approval for usage since 2014 and has also been available under terms similar to the MAA to DMD patients in Scotland since 2021.

Patients 98

Patients Medicine FDA Management 98

pharmaphorum

AUGUST 16, 2022

First approved in 2014, the drug is also used for a range of indications across ovarian, breast, fallopian tube, peritoneal and pancreatic cancers, and remains one of AZ’s fastest growing oncology therapies, with sales rising 18% to almost $1.3 billion in the first half of this year. .

FDA 111

FDA Patients Sales Marketing 111

pharmaphorum

JANUARY 24, 2023

A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.

Manufacturing 111

Manufacturing Medicine Government Pharmaceutical manufacturing 111

pharmaphorum

OCTOBER 26, 2022

There are more than 200 lung disorders that can lead to pulmonary fibrosis. First approved back in 2014, it is still growing strongly, with its 2021 sales of €2.5 Boehringer is a well-established presence in the IPF treatment market with Ofev (nintedanib), one of the German drugmaker’s top-selling drugs.

Recruitment 98

Recruitment Prospecting Marketing Patients 98

pharmaphorum

SEPTEMBER 14, 2022

It’s worth recalling that Dekkers first announced his intention to step down in 2014, with Baumann elevated to the role of chef strategy and portfolio officer shortly afterwards to prepare him to take on the top job two years later.

Pharma 98

Pharma Management Leads Marketing 98

Pharmaceutical Technology

MAY 16, 2023

In the next 12 months, the organisation will conduct the work leading up to investigational new drug (IND) submissions for new gene therapies. The AMP was launched in 2014 as a partnership between the FDA , the National Institutes for Health, and several public and private organisations.

Manufacturing 90

Manufacturing Patients Medicine FDA 90

Pharmaceutical Technology

APRIL 3, 2023

According to GlobalData’s Clinical Trials Database, gene therapy trials represent a 0.91% share of all planned trials in 2023, up from just 0.25% in 2014. GlobalData, the parent company of Pharmaceutical Technology, outlines a rise in gene therapy trials in 2023, in line with the growing market Fáber describes.

Media 98

Media Pharmaceutical Marketing Manufacturing 98

European Pharmaceutical Review

MAY 16, 2023

In 2014, the first stem-cell therapy was recommended for approval in EU by the European Medicines Agency (EMA). The stem cell therapy offered these outcomes because “reduced inflammation resulting from the activation of MPCs may decrease plaque instability, which is what leads to heart attacks and strokes.” million by 2031.

Manufacturing 104

Manufacturing Medicine Marketing Medical 104

pharmaphorum

AUGUST 4, 2022

When mutations occur it can lead to a wide range of disease, called laminopathies. One manifestation can be dilated cardiomyopathy, where the muscles of the heart become thin and stretched, making it harder to pump blood to the rest of the body, which can lead to heart failure. There are no therapies for LMNA-related DCM.

Biopharma 64

Biopharma Leads Patients Medical 64

pharmaphorum

JANUARY 3, 2023

during the lead-in pre-treatment period of at least six months. SPK-9001 was licensed by Pfizer from Spark Therapeutics pursuant to a December 2014 agreement, under which Spark was responsible for conducting all phase 1 and 2 studies for the gene therapy. for the 12 months from week 12 to month 15 compared to an ABR of 4.43

Medicine 98

Medicine Engineering Safety FDA 98

European Pharmaceutical Review

JANUARY 18, 2024

GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023. billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006). million in sales by 2032. percent sales expected in 2032 within the seven major markets.

Marketing 98

Marketing Sales Pharmacology Pharma 98

pharmaphorum

JANUARY 3, 2023

A pharmacologist by training, Rawlins was the founding chairman of health technology assessment (HTA) agency NICE , leading the organisation from its inception in 1999 until 2013, and hired Sir Andrew Dillon to become the organisation’s founding chief executive.

Medicine 52

Medicine Side effects Safety Healthcare 52

Pharmaceutical Technology

SEPTEMBER 5, 2022

On 23 August, at a Reuters Newsmakers online forum, Soriot announced his interest in increasing AstraZeneca’s portfolio of bolt-on acquisitions leading up to 2025. In 2014, AstraZeneca acquired Spain’s Almirall , along with the latter’s respiratory franchise, for an initial consideration of $875 million on completion and up to $1.22

FDA 114

FDA Pharmaceutical Biopharma Pharma 114

Legacy MEDSearch

JUNE 15, 2023

Founded in 2014, the company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. Cala Health’s products are the only FDA-cleared, clinically validated non-invasive devices for the relief of hand tremors so patients with essential tremor can return to the moments that matter.

Patients 98

Patients Recruitment Pharmacology Management 98

pharmaphorum

JULY 9, 2014

The global pharmaceutical market passes a significant milestone in 2014: reaching one trillion US dollars in total value. This study indicates that in the wider global context, the UK still matters for launch as one of the lead developed markets which account for the overwhelming majority of the early years of new chemical entity sales.

Marketing 52

Marketing Digital Media Pharma Engineering 52

European Pharmaceutical Review

JULY 26, 2024

The pharmaceutical company licensed the gene therapy DURVEQTIX from Spark ® Therapeutics in December 2014. However,] DURVEQTIX has shown the potential to offer long-term bleed protection in a one-time dose, reducing or eliminating bleeds for the appropriate patients with haemophilia B,” de Germay continued.

Food and Drug Administration 52

Food and Drug Administration Engineering Food Patients 52

European Pharmaceutical Review

SEPTEMBER 20, 2023

Conversely, poor analytical characterisation will likely lead to questions from regulators and, without sufficient product and process knowledge, an IND or BLA that is eventually deemed incomplete. Incorrect DNA sequences can also lead to high levels of SVs. While SVs are typically present at less than 0.1

Patients 98

Patients Manufacturing Leads Safety 98

European Pharmaceutical Review

DECEMBER 20, 2023

Stakeholder reaction to original EC proposals suggests that changes are considered more favourable for generic/biosimilar manufacturers, given reduced RDP periods could lead to earlier generic/biosimilar entry for both non-orphan and orphan drugs ( see Figure 2 ). By contrast, orphan drugs could become less profitable, more risky investments.

Biopharma 98

Biopharma Pharmaceutical Medicine Manufacturing 98

Pharmaceutical Technology

JANUARY 23, 2023

Out of the seven biologics approved to treat moderate to severe CD in adults, only the anti-TNFαs, Remicade (infliximab), and Humira (adalimumab), have been approved for paediatric patients, with Humira receiving the most recent approval in 2014.

Medical 59

Medical Ethics Specialization Physicians 59

Pharmaceutical Technology

APRIL 12, 2023

Additionally, this could lead to various epidemiological shifts such as certain cancers including colorectal cancer being diagnosed at a more severe stage or increases in the incidence of infectious diseases like HIV.

Insurance 52

Insurance Leads Medical 52

European Pharmaceutical Review

JUNE 27, 2023

Our lead candidate MaaT013, a donor-derived, standardised, high-richness, high-diversity MET is currently being evaluated in a Phase III trial (ARES) in Europe and in an Early Access Program in Europe, mostly in acute Graft-versus Host Disease (aGvHD), a severe complication following stem cell transplantation.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Medicine Pharma 105

pharmaphorum

NOVEMBER 16, 2022

Ovarian cancer is the eighth most common cancer worldwide and is the leading cause of death from gynaecological cancers in the US: approximately 20,000 patients are diagnosed annually in the US alone, and 13,000 patients will die from it. Between 35% to 40% of ovarian cancer patients express high levels of FR?

FDA 69

FDA Patients Safety Medicine 69

CloserIQ

OCTOBER 10, 2018

Founded 2014. They’ve worked with leading clients such as Twitter and Mercedes Benz. Founded 2014. CloudHealth Technologies offers a market-leading cloud management platform that helps businesses optimize different cloud environments. Founded 2014. Founded 2014. 51-100 employees. 107 million in funding.

Sales 76

Sales Management Education Marketing 76

pharmaphorum

AUGUST 19, 2022

Pharming attempted to extend the use of its C1 esterase inhibitor product Ruconest (conestat alfa) into the prevention setting, having won FDA approval for acute treatment of attacks in 2014, but was knocked back by the regulator. It is administered as an intravenous injection.

Sales 52

Sales Pharma Patients Medicine 52

Clarivate

APRIL 14, 2022

On this list, Ukraine was 13th in the Science and Technology category among 124 other countries in 2014, and 14th among 163 countries in 2020. Our data shows that the Ministry of Education and Science of Ukraine are leading local authorship in this area. Figure 2: N umber of Ukraine publications across SDGs. Source: Web of Science.

Government 133

Government Education Distribution Food 133

Map My Customers

NOVEMBER 19, 2022

Microsoft discontinued its mapping application, MapPoint, in late 2014. Map My Customers saves planning and routing time, generates leads, segments accounts, tracks sales cadences, and more! Superior security capabilities to protect access to sensitive business data. It has native CRM integration with Microsoft Dynamics.

CRM 75

CRM Sales Prospecting B2B Sales 75

Clarivate

MAY 13, 2024

Insurance exchanges underwent their largest single-year enrollment growth since their inception in 2014, pushing exchange enrollment to yet another all-time high. This may also lead to gaps in care, reduced drug adherence, increased emergency room visits and a decline in chronic care management. The post The U.S.

Insurance 52

Insurance Marketing Healthcare Healthcare 52

European Pharmaceutical Review

FEBRUARY 22, 2023

Although effective, the inconvenience of regular injections can lead to poor patient adherence, with studies showing that persistence and adherence are generally better for oral medications compared with injections. He has been a key member of the executive team, most recently serving as the company’s Vice President, Strategy since 2014.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Safety Pharmaceutical 105

PM360

SEPTEMBER 8, 2023

GoodRx is a leading resource for people with diabetes to find prescription savings and information, having helped almost 2.5 While there are recent efforts to curb the prices of insulin, GoodRx research 5 shows the average cash price for insulin rose 54% from 2014 to 2019, and only decreased 7.1% First, some good news about diabetes.

Doctors 72

Doctors Prescription Specialization Medical 72

European Pharmaceutical Review

DECEMBER 21, 2022

Production and value creation can be regionalised and decentralised, which could lead to a more resilient economic structure. During his time at Genentech Stefan has advanced several small molecules and new modalities (antibody‑drug conjugates, oligonucleotides and peptides) into the clinic as lead chemist and technical development leader.

Manufacturing 97

Manufacturing Pharmaceutical Healthcare Healthcare 97

European Pharmaceutical Review

JANUARY 29, 2024

26 assessed FDA field reports between 23005 and 2014 and highlighted that poorly soluble instant release (IR) drug products showed the most dissolution test failures, followed by poorly soluble modified release (MR) drug products and then highly soluble MR drug products. 25 Sun et al.

Pharmaceutical 111

Pharmaceutical Food and Drug Administration Medicine FDA 111

PM360

NOVEMBER 16, 2023

Using generative AI to create AI representatives for team leads wasn’t the most obvious application of the technology, but it is proving to provide them tremendous support and value in project planning.”

Specialization 52

Specialization Media Leads Medical 52

pharmaphorum

JANUARY 13, 2023

” Cardiovascular disease is the leading cause of death and disability in the UK, causing around 7% of deaths each year, and high cholesterol a significant risk factor for it, said NICE. It is the second time that NICE has lowered the threshold for statin prescribing, after cutting it from 20% to 10% in 2014.

Side effects 52

Side effects Patients Doctors Medical 52

European Pharmaceutical Review

JULY 5, 2022

A Scientific Advisory Board of leading oncologists support the concept of a daily tablet formulation of irinotecan, such as Oncoral, and see its value as an additional treatment option for cancer patients, especially those in later disease stages. accessdata.fda.gov/drugsatfda_docs/label/2014/020571s048lbl.pdf [Accessed 25.01.22].

Patients 104

Patients Food and Drug Administration Side effects Safety 104